Which has better earnings & valuation, OCS or ABOS?

Oculis is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oculis N/A N/A -$119.44M -$2.13 N/A Acumen Pharmaceuticals N/A N/A -$121.33M -$1.86 N/A

Does the media prefer OCS or ABOS?

In the previous week, Oculis had 6 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 7 mentions for Oculis and 1 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.34 beat Oculis' score of 1.07 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acumen Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, ABOS or AVTE?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acumen Pharmaceuticals N/A N/A -$121.33M -$1.86 N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is ABOS or AVTE more profitable?

Aerovate Therapeutics' return on equity of -90.19% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acumen Pharmaceuticals N/A -123.07% -79.41% Aerovate Therapeutics N/A -90.19% -77.47%

Does the media refer more to ABOS or CRMD?

In the previous week, CorMedix had 1 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 2 mentions for CorMedix and 1 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.34 beat CorMedix's score of 0.00 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CorMedix 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ALT or ABOS?

In the previous week, Altimmune had 10 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 11 mentions for Altimmune and 1 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.34 beat Altimmune's score of -0.32 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral Acumen Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ZVRA or ABOS?

In the previous week, Zevra Therapeutics had 8 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 9 mentions for Zevra Therapeutics and 1 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.34 beat Zevra Therapeutics' score of 0.05 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Acumen Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Acumen Pharmaceuticals (ABOS) Competitors

$2.20 +0.03 (+1.15%)

As of 10:59 AM Eastern

Compare

ABOS vs. OCS, AVTE, CRMD, ALT, and ZVRA

Should you buy Acumen Pharmaceuticals stock or one of its competitors? MarketBeat compares Acumen Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Acumen Pharmaceuticals include Oculis (OCS), Aerovate Therapeutics (AVTE), CorMedix (CRMD), Altimmune (ALT), and Zevra Therapeutics (ZVRA).

How does Acumen Pharmaceuticals compare to Oculis?

Oculis (NASDAQ:OCS) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Acumen Pharmaceuticals has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

Oculis is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	N/A	N/A	-$119.44M	-$2.13	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A

In the previous week, Oculis had 6 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 7 mentions for Oculis and 1 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.34 beat Oculis' score of 1.07 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oculis has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market.

Oculis currently has a consensus target price of $38.33, indicating a potential upside of 214.34%. Acumen Pharmaceuticals has a consensus target price of $8.00, indicating a potential upside of 262.81%. Given Acumen Pharmaceuticals' higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Oculis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

22.3% of Oculis shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 10.2% of Acumen Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Oculis and Acumen Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Aerovate Therapeutics?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

Aerovate Therapeutics' return on equity of -90.19% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 10.2% of Acumen Pharmaceuticals shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Acumen Pharmaceuticals has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Acumen Pharmaceuticals presently has a consensus target price of $8.00, suggesting a potential upside of 262.81%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Acumen Pharmaceuticals is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Acumen Pharmaceuticals had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 1 mentions for Acumen Pharmaceuticals and 0 mentions for Aerovate Therapeutics. Acumen Pharmaceuticals' average media sentiment score of 1.34 beat Aerovate Therapeutics' score of 0.00 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Acumen Pharmaceuticals	Positive
Aerovate Therapeutics	Neutral

Summary

Acumen Pharmaceuticals beats Aerovate Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to CorMedix?

Acumen Pharmaceuticals (NASDAQ:ABOS) and CorMedix (NASDAQ:CRMD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

In the previous week, CorMedix had 1 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 2 mentions for CorMedix and 1 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.34 beat CorMedix's score of 0.00 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CorMedix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CorMedix has a net margin of 45.25% compared to Acumen Pharmaceuticals' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
CorMedix	45.25%	45.57%	24.76%

CorMedix has higher revenue and earnings than Acumen Pharmaceuticals. Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A
CorMedix	$311.71M	1.91	$163.05M	$2.13	3.57

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 10.2% of Acumen Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Acumen Pharmaceuticals presently has a consensus target price of $8.00, indicating a potential upside of 262.81%. CorMedix has a consensus target price of $14.86, indicating a potential upside of 95.49%. Given Acumen Pharmaceuticals' higher possible upside, equities research analysts plainly believe Acumen Pharmaceuticals is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Acumen Pharmaceuticals has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

Summary

CorMedix beats Acumen Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Altimmune?

Altimmune (NASDAQ:ALT) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

In the previous week, Altimmune had 10 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 11 mentions for Altimmune and 1 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.34 beat Altimmune's score of -0.32 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Altimmune has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market.

78.1% of Altimmune shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 1.6% of Altimmune shares are held by insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Altimmune has higher revenue and earnings than Acumen Pharmaceuticals. Altimmune is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	14,512.32	-$88.09M	-$0.93	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A

Acumen Pharmaceuticals has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-42.57%	-35.57%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

Altimmune presently has a consensus price target of $15.71, indicating a potential upside of 426.44%. Acumen Pharmaceuticals has a consensus price target of $8.00, indicating a potential upside of 262.81%. Given Altimmune's stronger consensus rating and higher possible upside, equities research analysts clearly believe Altimmune is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Altimmune beats Acumen Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

In the previous week, Zevra Therapeutics had 8 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 9 mentions for Zevra Therapeutics and 1 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.34 beat Zevra Therapeutics' score of 0.05 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zevra Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

Zevra Therapeutics has higher revenue and earnings than Acumen Pharmaceuticals. Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	5.69	$83.23M	$1.99	5.15
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A

35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 3.7% of Zevra Therapeutics shares are owned by insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Zevra Therapeutics presently has a consensus price target of $26.86, indicating a potential upside of 162.02%. Acumen Pharmaceuticals has a consensus price target of $8.00, indicating a potential upside of 262.81%. Given Acumen Pharmaceuticals' higher possible upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Zevra Therapeutics has a net margin of 101.58% compared to Acumen Pharmaceuticals' net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

Summary

Zevra Therapeutics beats Acumen Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Get Acumen Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABOS vs. The Competition

Export

Metric	Acumen Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$158.55M	$3.53B	$6.79B	$12.85B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-1.18	7.36	280.19	25.31
Price / Sales	N/A	1,266.96	645.11	114.43
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	1.90	16.90	11.01	6.29
Net Income	-$121.33M	-$12.52M	$3.48B	$347.49M
7 Day Performance	-3.29%	1.39%	1.81%	2.25%
1 Month Performance	-19.53%	-6.48%	-3.36%	-2.82%
1 Year Performance	65.79%	48.83%	62.28%	19.84%

Acumen Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABOS Acumen Pharmaceuticals	2.3464 of 5 stars	$2.21 +1.1%	$8.00 +262.8%	+61.5%	$158.55M	N/A	N/A	20	Positive News Upcoming Earnings
OCS Oculis	3.4351 of 5 stars	$10.90 -1.1%	$38.33 +251.8%	-32.8%	$631.11M	$1.45M	N/A	2	News Coverage Positive News Upcoming Earnings
AVTE Aerovate Therapeutics	N/A	$19.95 -0.6%	N/A	+186.6%	$578.25M	N/A	N/A	20	High Trading Volume
CRMD CorMedix	1.7314 of 5 stars	$7.29 -4.1%	$14.86 +103.9%	-35.1%	$575.82M	$311.71M	3.45	30
ALT Altimmune	2.025 of 5 stars	$2.97 +0.2%	$15.71 +430.0%	-16.9%	$572.73M	$36K	N/A	50	Positive News Upcoming Earnings High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABOS) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acumen Pharmaceuticals (ABOS) Competitors

ABOS vs. OCS, AVTE, CRMD, ALT, and ZVRA

How does Acumen Pharmaceuticals compare to Oculis?

Summary

How does Acumen Pharmaceuticals compare to Aerovate Therapeutics?

Summary

How does Acumen Pharmaceuticals compare to CorMedix?

Summary

How does Acumen Pharmaceuticals compare to Altimmune?

Summary

How does Acumen Pharmaceuticals compare to Zevra Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS vs. The Competition

Acumen Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acumen Pharmaceuticals (ABOS) Competitors

ABOS vs. OCS, AVTE, CRMD, ALT, and ZVRA

How does Acumen Pharmaceuticals compare to Oculis?

Is OCS or ABOS more profitable?

Which has better earnings & valuation, OCS or ABOS?

Does the media prefer OCS or ABOS?

Which has more volatility & risk, OCS or ABOS?

Do analysts prefer OCS or ABOS?

Do insiders & institutionals have more ownership in OCS or ABOS?

Summary

How does Acumen Pharmaceuticals compare to Aerovate Therapeutics?

Is ABOS or AVTE more profitable?

Do institutionals & insiders hold more shares of ABOS or AVTE?

Which has better valuation and earnings, ABOS or AVTE?

Which has more volatility and risk, ABOS or AVTE?

Do analysts prefer ABOS or AVTE?

Does the media refer more to ABOS or AVTE?

Summary

How does Acumen Pharmaceuticals compare to CorMedix?

Does the media refer more to ABOS or CRMD?

Is ABOS or CRMD more profitable?

Which has higher earnings & valuation, ABOS or CRMD?

Do institutionals and insiders believe in ABOS or CRMD?

Do analysts recommend ABOS or CRMD?

Which has more volatility and risk, ABOS or CRMD?

Summary

How does Acumen Pharmaceuticals compare to Altimmune?

Does the media prefer ALT or ABOS?

Which has more volatility & risk, ALT or ABOS?

Do insiders and institutionals have more ownership in ALT or ABOS?

Which has higher earnings and valuation, ALT or ABOS?

Is ALT or ABOS more profitable?

Do analysts rate ALT or ABOS?

Summary

How does Acumen Pharmaceuticals compare to Zevra Therapeutics?

Does the media prefer ZVRA or ABOS?

Which has more volatility and risk, ZVRA or ABOS?

Which has better earnings and valuation, ZVRA or ABOS?

Do insiders & institutionals believe in ZVRA or ABOS?

Do analysts recommend ZVRA or ABOS?

Is ZVRA or ABOS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS vs. The Competition

Acumen Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools